Nasopharyngeal cancer is usually treated with immunotherapy, which blocks PD-1 receptors on the surface of immune cells, whose job is to hunt pathogens. The truth is, cancer cells use these receptors to effectively disable the body’s natural defense systems.
Because the COVID-19 vaccine stimulates the body’s immune response through the same cell signaling pathways, scientists needed to know how the vaccine might affect this cancer treatment. Researchers analyzed the records of 1,537 patients treated for nasopharyngeal cancer at 23 hospitals. Of these, 373 people were vaccinated with SinoVac.
These patients appeared to respond significantly better to anticancer therapy than unvaccinated patients. Additionally, they did not experience serious side effects most of the time.
News cannot be equated with a doctor’s prescription. Consult an expert before making a decision.
Source: Ferra
